[{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Travoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Travoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Travoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"AffaMed Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocular Therapeutix","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.10000000000000001,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ AffaMed Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Ocular Therapeutix \/ AffaMed Therapeutics"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"AffaMed Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Ocular Therapeutix","highestDevelopmentStatusID":"15","companyTruncated":"Ocular Therapeutix \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Solution","sponsorNew":"Ocular Therapeutix \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"Ocular Therapeutix \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Solution","sponsorNew":"Ocular Therapeutix \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"Ocular Therapeutix \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Implant, Sustained Release","sponsorNew":"Ocular Therapeutix \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"Ocular Therapeutix \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Implant, Sustained Release","sponsorNew":"Ocular Therapeutix \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"Ocular Therapeutix \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"Ocular Therapeutix \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Implant, Sustained Release","sponsorNew":"Ocular Therapeutix \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"Ocular Therapeutix \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"Ocular Therapeutix \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"Ocular Therapeutix \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"Ocular Therapeutix \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"Ocular Therapeutix \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"OTX-CSI","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"Adrenergic-alpha-1 receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intraocular Solution","sponsorNew":"Ocular Therapeutix \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"Ocular Therapeutix \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Fortrea | Duke University","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ocular Therapeutix \/ Fortrea | Duke University","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Fortrea | Duke University"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Fortrea | Duke University","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OTX-TKI","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ocular Therapeutix \/ Fortrea | Duke University","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Fortrea | Duke University"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.12,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Jefferies"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.12,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Jefferies"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Venrock Healthcare Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0.33000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.33000000000000002,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Venrock Healthcare Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Venrock Healthcare Capital Partners"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"AffaMed Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Insert","sponsorNew":"Ocular Therapeutix \/ Ocular Therapeutix","highestDevelopmentStatusID":"15","companyTruncated":"Ocular Therapeutix \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Cleveland Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Insert","sponsorNew":"Ocular Therapeutix \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"Ocular Therapeutix \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Ophthalmic Insert","sponsorNew":"Ocular Therapeutix \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"Ocular Therapeutix \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Ophthalmic Insert","sponsorNew":"Ocular Therapeutix \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"Ocular Therapeutix \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Implant","sponsorNew":"Ocular Therapeutix \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"Ocular Therapeutix \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"Ocular Therapeutix \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"Ocular Therapeutix \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Insert","sponsorNew":"Ocular Therapeutix \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"Ocular Therapeutix \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Implant, Sustained Release","sponsorNew":"Ocular Therapeutix \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"Ocular Therapeutix \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Insert","sponsorNew":"Ocular Therapeutix \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"Ocular Therapeutix \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Insert","sponsorNew":"Ocular Therapeutix \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"Ocular Therapeutix \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"AffaMed Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Implant","sponsorNew":"Ocular Therapeutix \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"Ocular Therapeutix \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Insert","sponsorNew":"Ocular Therapeutix \/ Ocular Therapeutix","highestDevelopmentStatusID":"9","companyTruncated":"Ocular Therapeutix \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"OTX-DED","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"OTX-DED","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Ophthalmic Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Titan Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Implant","sponsorNew":"Ocular Therapeutix \/ Ocular Therapeutix","highestDevelopmentStatusID":"4","companyTruncated":"Ocular Therapeutix \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"OTX-TKI","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"OTX-TKI","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"OTX-TIC","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Mosaic Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocular Therapeutix \/ Ocular Therapeutix","highestDevelopmentStatusID":"2","companyTruncated":"Ocular Therapeutix \/ Ocular Therapeutix"}]

Find Clinical Drug Pipeline Developments & Deals by Ocular Therapeutix

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Axpaxli (axitinib) is an investigational bioresorbable, hydrogel implant with axitinib, small molecule TKI with anti-angiogenic properties. It is being developed for the treatment of wet AMD.

                          Product Name : Axpaxli

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 15, 2024

                          Lead Product(s) : Axitinib

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Axpaxli (axitinib) is an investigational bioresorbable, hydrogel implant incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor for the treatment of WET AMD.

                          Product Name : Axpaxli

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 30, 2024

                          Lead Product(s) : Axitinib

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 11, 2024

                          Lead Product(s) : OTX-TKI

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Fortrea | Duke University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Axpaxli (axitinib) is an investigational bioresorbable, hydrogel implant with axitinib, small molecule TKI with anti-angiogenic properties. It is being developed for the treatment of wet AMD.

                          Product Name : Axpaxli

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 08, 2024

                          Lead Product(s) : Axitinib

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Paxtrava (travoprost intracameral implant) is a prostaglandin analog. It is being evaluated for the treatment of patients with open-angle glaucoma or ocular hypertension.

                          Product Name : Paxtrava

                          Product Type : HPAPI

                          Upfront Cash : Inapplicable

                          June 04, 2024

                          Lead Product(s) : Travoprost

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Axpaxli (axitinib) is a bioresorbable hydrogel implant incorporating axitinib, a multi-target tyrosine kinase inhibitor, being developed for diabetic retinopathy treatment.

                          Product Name : Axpaxli

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 18, 2024

                          Lead Product(s) : Axitinib

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : The company intends to use the net proceeds from the private placement to accelerate the clinical development of Axpali (axitinib) for the treatment of wet age-related macular degeneration.

                          Product Name : Axpaxli

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 22, 2024

                          Lead Product(s) : Axitinib

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Venrock Healthcare Capital Partners

                          Deal Size : $325.0 million

                          Deal Type : Private Placement

                          blank

                          08

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Axpaxli (axitinib) is a bioresorbable hydrogel implant incorporating axitinib, developed for wet age-related macular degeneration treatment.

                          Product Name : Axpaxli

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 13, 2024

                          Lead Product(s) : Axitinib

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 25, 2024

                          Lead Product(s) : Axitinib

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Fortrea | Duke University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Axpaxli (axitinib) is an investigational hydrogel implant containing axitinib, being evaluated in phase 3 trials for treating wet AMD and other retinal diseases.

                          Product Name : Axpaxli

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 25, 2024

                          Lead Product(s) : Axitinib

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank